Exercise price determined for the exercise of warrants series TO 9 in Alligator Bioscience AB
Alligator Bioscience AB (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series ...
Notice of extraordinary general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator sharpens focus on mitazalimab and announces cost reduction program to maximize long-term value creation
Sharpening focus on preparing mitazalimab for Phase 3 and continuing partnering discussions Planned reduction of workforce, mainly wit ...
Alligator Bioscience carries out a rights issue of units of approximately SEK 280 million and raises bridge loans
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator announces sale of future financial commitments for two bispecific antibodies to Orion Corporation
Transaction valued at €3.5 million The partners have enjoyed a successful discovery collaboration since 2021 Lund, Sweden – Allig ...
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Alligator Bioscience and Aptevo Therapeutics report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, with ...
Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer at SITC 2024
The data contain efficacy results and correlative outcomes with biomarkers based on a median follow-up of 18 months in OPTIMIZE-1 trial Conf ...
Nomination Committee appointed in respect of AGM 2025 in Alligator Bioscience AB
Lund, Sweden, October 31, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in prepa ...
Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces participation in the following conferences during Q4 202 ...